Device Trial Radar · NCT04508153
Pelvic Floor Muscle Training With a Digital Therapeutic Device to Standard Exercises for Stress Urinary Incontinence
Last checked: Nov 19, 2026Latest source record: Dec 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
369
Actual
Start
Oct 1, 2020
Primary completion
Apr 23, 2021
Study completion Sep 1, 2021
Sponsor
- Lead sponsor
- Renovia, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- OBVIO HEALTH USA, Inc.; University of Alabama at Birmingham
- First posted
- Aug 11, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A virtual prospective randomized controlled study to evaluate the efficacy of using the leva® Pelvic Digital Health System (PDHS) to perform PFMT compared to a standard home exercise home program for the treatment of SUI/SMUI. The treatment part of the study lasts eight weeks and has two arms. One group will receive routine care consisting of at-home Kegel exercises, and the other will be provided with a leva® device and instructions for use. Subjects in both groups will be assessed at baseline, then at 4 and 8 weeks for change and improvement of their symptoms. They will also be assessed at 6 and12 months after study completion.
Conditions
- Stress Urinary Incontinence
Interventions
Leva Pelvic Digital Health SystemDevice
Pelvic floor muscle training using the pelvic digital health system to treat pelvic floor disorders, specifically stress urinary incontinence.
Kegel exercisesOther
Pelvic floor muscle training (PFMT), commonly referred to as "Kegel" exercises, is a first line conservative treatment for pelvic floor disorders, specifically stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (SMUI).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy - Urogenital Distress Inventory (UDI-6)Time frame: Baseline, 4 weeks, 8 weeks, 6 months and 12 months
- Efficacy - Bladder diariesTime frame: Baseline and 8 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama *** Virtual Trial May be enrolled from any US Location
Birmingham, Alabama
Southern California Permanente Medical Group*** Virtual Trial May be enrolled from any US Location
Irvine, California
University of New Mexico *** Virtual Trial May be enrolled from any US Location
Albuquerque, New Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.